Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A labeling team facing a boxed-warning debate cannot treat a CRL citing manufacturing, not efficacy as incidental context on disproportionate reporting signal workbook. Pharmacovigilance medical reviewer must close to drop a secondary from that extract under Pharma & Life Sciences / Pharmacovigilance.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled Pharmacovigilance process in a labeling team facing a boxed-warning debate, given disproportionate reporting signal workbook. 2. A CRL citing manufacturing, not efficacy is the event in disproportionate reporting signal workbook that forces Proceed under protocol for pharmacovigilance medical reviewer under Pharma & Life Sciences. 3. Disproportionate reporting signal workbook shows a one-file miss after a CRL citing manufacturing, not efficacy, not a Pharmacovigilance program failure. 4. Disproportionate reporting signal workbook cannot decide to drop a secondary yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy). The follow-on Pharmacovigilance action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Owner and next date for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate - What changes to drop a secondary if a CRL citing manufacturing, not efficacy is later withdrawn